Alan List - 12 Feb 2026 Form 4 Insider Report for TuHURA Biosciences, Inc./NV (HURA)

Reporting relationship: Director
Issuer ticker: HURA
Reported as of: 12 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Feb 2026, 16:16:01 UTC
Prior SEC filing: 06 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Dan Dearborn as Power of Attorney for Alan List

Key filing fact

Alan List filed Form 4 for TuHURA Biosciences, Inc./NV (HURA) on 17 Feb 2026.

Key facts

This page summarizes Alan List's Form 4 filing for TuHURA Biosciences, Inc./NV (HURA).
1 reported transaction and 2 derivative rows are listed below.
Accepted by SEC: 17 Feb 2026, 16:16.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001858530 Primary reporting owner

List Alan

Relationship: Director
Address: 10500 UNIVERSITY CENTER DRIVE, SUITE 110, TAMPA
Signature: /s/ Dan Dearborn as Power of Attorney for Alan List
Signature date: 17 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HURA transaction Derivative

Options (Right to Buy)

Award

Transaction value: $0
Shares: +156,240
Change %
Price: $0.000000
Shares after: 156,240
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 156,240
Exercise price: $1.29
Footnotes: F1

HURA holding Derivative

Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 51,275
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 51,275
Exercise price: $4.11
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

Footnote F2

Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.